295 related articles for article (PubMed ID: 26022710)
21. Colony growth and self renewal of plasma cell precursors in multiple myeloma.
Takahashi T; Lim B; Jamal N; Tritchler D; Lockwood G; McKinney S; Bergsagel DE; Messner HA
J Clin Oncol; 1985 Dec; 3(12):1613-23. PubMed ID: 4067612
[TBL] [Abstract][Full Text] [Related]
22. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.
Rajkumar SV
Hematology Am Soc Hematol Educ Program; 2005; ():340-5. PubMed ID: 16304401
[TBL] [Abstract][Full Text] [Related]
23. Asymptomatic monoclonal gammopathies.
Bories C; Jagannath S
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S78-86. PubMed ID: 25486961
[TBL] [Abstract][Full Text] [Related]
24. Smoldering Multiple Myeloma: Who and When to Treat.
Mateos MV; González-Calle V
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
[TBL] [Abstract][Full Text] [Related]
25. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma.
Ravi P; Kumar S; Larsen JT; Gonsalves W; Buadi F; Lacy MQ; Go R; Dispenzieri A; Kapoor P; Lust JA; Dingli D; Lin Y; Russell SJ; Leung N; Gertz MA; Kyle RA; Bergsagel PL; Rajkumar SV
Blood Cancer J; 2016 Jul; 6(7):e454. PubMed ID: 27471870
[TBL] [Abstract][Full Text] [Related]
26. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma.
Rosiñol L; Carrió A; Bladé J; Queralt R; Aymerich M; Cibeira MT; Esteve J; Rozman M; Campo E; Montserrat E
Br J Haematol; 2005 Sep; 130(5):729-32. PubMed ID: 16115129
[TBL] [Abstract][Full Text] [Related]
27. Clinical and prognostic significance of bone marrow abnormalities in the appendicular skeleton detected by low-dose whole-body multidetector computed tomography in patients with multiple myeloma.
Nishida Y; Matsue Y; Suehara Y; Fukumoto K; Fujisawa M; Takeuchi M; Ouchi E; Matsue K
Blood Cancer J; 2015 Jul; 5(7):e329. PubMed ID: 26230953
[TBL] [Abstract][Full Text] [Related]
28. Management of asymptomatic myeloma patients.
Mateos MV
Expert Rev Hematol; 2015 Feb; 8(1):19-27. PubMed ID: 25363073
[TBL] [Abstract][Full Text] [Related]
29. Smoldering multiple myeloma: to treat or not to treat.
Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Martino M; Morabito F; Gentili S
Expert Opin Pharmacother; 2015 Apr; 16(6):785-90. PubMed ID: 25659943
[TBL] [Abstract][Full Text] [Related]
30. Pathway-based network analysis of myeloma tumors: monoclonal gammopathy of unknown significance, smoldering multiple myeloma, and multiple myeloma.
Dong L; Chen CY; Ning B; Xu DL; Gao JH; Wang LL; Yan SY; Cheng S
Genet Mol Res; 2015 Aug; 14(3):9571-84. PubMed ID: 26345890
[TBL] [Abstract][Full Text] [Related]
31. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957
[TBL] [Abstract][Full Text] [Related]
32. Role of flow cytometry of peripheral blood and bone marrow aspirates in early myeloma.
Yuan CM; Stetler-Stevenson M
Semin Hematol; 2011 Jan; 48(1):32-8. PubMed ID: 21232656
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
[TBL] [Abstract][Full Text] [Related]
34. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.
López-Corral L; Gutiérrez NC; Vidriales MB; Mateos MV; Rasillo A; García-Sanz R; Paiva B; San Miguel JF
Clin Cancer Res; 2011 Apr; 17(7):1692-700. PubMed ID: 21325290
[TBL] [Abstract][Full Text] [Related]
35. [The pathology of smoldering multiple myeloma].
Shibayama H
Nihon Rinsho; 2015 Jan; 73(1):33-7. PubMed ID: 25626300
[TBL] [Abstract][Full Text] [Related]
36. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
[TBL] [Abstract][Full Text] [Related]
37. [Clinical courses and risk factors for progression of smoldering multiple myeloma: a nationwide cohort study in Japan].
Takamatsu Y; Muta T
Rinsho Ketsueki; 2015 Aug; 56(8):1005-10. PubMed ID: 26345559
[TBL] [Abstract][Full Text] [Related]
38. Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma.
Chim CS; Liang R; Leung MH; Kwong YL
J Clin Pathol; 2007 Jan; 60(1):104-6. PubMed ID: 17213358
[TBL] [Abstract][Full Text] [Related]
39. High-risk smoldering myeloma: Perspective on watchful monitoring.
Leng S; Lentzsch S
Semin Oncol; 2016 Dec; 43(6):697-699. PubMed ID: 28061989
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Rajkumar SV; Lacy MQ; Kyle RA
Blood Rev; 2007 Sep; 21(5):255-65. PubMed ID: 17367905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
